Prediction markets entering biotech may sound innovative on the surface, but they also introduce a new layer of risk to an industry already defined by uncertainty. Clinical trials influence investor confidence, patient enrollment, company valuations, and ultimately whether therapies ever reach the market.

In an interview with Fierce Biotech, Managing Partner Michael Abrams warned of the impact that clinical trial prediction markets may have, likening it to the wild west.

In a situation where you can win a lot of money with an accurate prediction regarding the outcome of a clinical trial, it’s an invitation to those with access to non-public information to compromise their integrity to make the money.

For smaller biotech companies, especially, perception can quickly become reality. A negative prediction cycle surrounding a trial could impact funding, recruitment, and public confidence long before actual data is finalized.

As these platforms expand, regulators, investors, and biotech leaders will need to grapple with where transparency ends, and market manipulation risk begins.

Read the full story at fiercebiotech.com.